Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to determine a safe, tolerable and effective dose of sotatercept that results in the greatest frequency of erythroid hematological improvement (HI-E) in patients with anemia and low- or intermediate-1 risk MDS.
Critère d'inclusion
- Anemia and low or intermediate-1 risk myelodysplastic syndromes, or non-proliferative chronic myelomonocytic leukemia (CMML)